Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00113607




Registration number
NCT00113607
Ethics application status
Date submitted
9/06/2005
Date registered
10/06/2005
Date last updated
27/06/2014

Titles & IDs
Public title
An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer
Scientific title
An Open-Label Multicenter Randomized Phase 3 Study Comparing the Combination of DOXIL/CAELYX and YONDELIS With DOXIL/CAELYX Alone in Subjects With Advanced Relapsed Ovarian Cancer
Secondary ID [1] 0 0
ET743-OVA-301
Secondary ID [2] 0 0
CR003448
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Ovarian Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Ovarian and primary peritoneal

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Trabectedin
Treatment: Drugs - DOXIL
Treatment: Drugs - Dexamethasone

Experimental: DOXIL + trabectedin - Combination arm - Trabectedin + DOXIL: DOXIL 30 mg/m2 intravenous (IV) infusion over 90 minutes + trabectedin 1.1 mg/m2 IV infusion over 3 hours every 3 weeks. patients will be premedicated with 20 mg dexamethasone or its equivalent IV infusion over 30 minutes prior to the DOXIL infusion.

Active comparator: DOXIL - Monotherapy arm - DOXIL: 50 mg/m2 IV infusion over 90 minutes every 4 weeks.


Treatment: Drugs: Trabectedin
Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.

Treatment: Drugs: DOXIL
Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.

Treatment: Drugs: Dexamethasone
Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Progression-Free Survival (PFS): Independent Radiologist Review
Timepoint [1] 0 0
From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years
Secondary outcome [1] 0 0
Overall Survival
Timepoint [1] 0 0
From the date of randomization until the date of death, as assessed for approximately 3 years
Secondary outcome [2] 0 0
Objective Response Rate (ORR) - Independent Radiologist Review
Timepoint [2] 0 0
From the date of randomization until the date of disease progression or death, as assessed for approximately 3 years
Secondary outcome [3] 0 0
Duration of Response: Independent Radiologist Review
Timepoint [3] 0 0
From the date of first documentation of response to the date of disease progression or death due to progressive disease, as assessed for approximately 3 years
Secondary outcome [4] 0 0
Median Area Under Curve (AUC) of Trabectedin.
Timepoint [4] 0 0
Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2
Secondary outcome [5] 0 0
Median Maximum Plasma Concentration (Cmax) of Trabectedin.
Timepoint [5] 0 0
Day 1 (Predose; 1.5 hour after start of infusion; 5 minutes, 2 hour and 6 to 20 hour after end of infusion); Day 8 (168 hour after end of infusion); and Day 15 (336 hour after end of infusion) at Cycles 1 and 2

Eligibility
Key inclusion criteria
* Histologically proven epithelial ovarian cancer, epithelial fallopian tube cancer, or primary peritoneal cancer
* Prior treatment with only 1 platinum based chemotherapy regimen
* Eastern Cooperative Oncology Group status of not more than 2
* Progression more than 6 months after the start of initial chemotherapy treatment
Minimum age
18 Years
Maximum age
No limit
Sex
Females
Can healthy volunteers participate?
No
Key exclusion criteria
* Treatment with more than 1 prior chemotherapy regimen
* Progression within 6 months after starting initial chemotherapy
* Prior exposure to anthracyclines
* Unwilling or unable to have central venous catheter
* Known clinically relevant central nervous system metastasis

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/04/2005
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/11/2010
Sample size
Target
Accrual to date
Final
672
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
- Adelaide
Recruitment hospital [2] 0 0
- Bentleigh
Recruitment hospital [3] 0 0
- Douglas
Recruitment hospital [4] 0 0
- St Leonards
Recruitment hospital [5] 0 0
- Toorak Gardens
Recruitment postcode(s) [1] 0 0
- Adelaide
Recruitment postcode(s) [2] 0 0
- Bentleigh
Recruitment postcode(s) [3] 0 0
- Douglas
Recruitment postcode(s) [4] 0 0
- St Leonards
Recruitment postcode(s) [5] 0 0
- Toorak Gardens
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Alabama
Country [2] 0 0
United States of America
State/province [2] 0 0
Arizona
Country [3] 0 0
United States of America
State/province [3] 0 0
California
Country [4] 0 0
United States of America
State/province [4] 0 0
Colorado
Country [5] 0 0
United States of America
State/province [5] 0 0
Connecticut
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Idaho
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Louisiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Minnesota
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Tennessee
Country [21] 0 0
United States of America
State/province [21] 0 0
Texas
Country [22] 0 0
Argentina
State/province [22] 0 0
Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Mendoza
Country [24] 0 0
Argentina
State/province [24] 0 0
Sante Fe
Country [25] 0 0
Belgium
State/province [25] 0 0
Edegem
Country [26] 0 0
Belgium
State/province [26] 0 0
Hasselt
Country [27] 0 0
Belgium
State/province [27] 0 0
Leuven
Country [28] 0 0
Belgium
State/province [28] 0 0
Wilrijk
Country [29] 0 0
Brazil
State/province [29] 0 0
Barretos
Country [30] 0 0
Brazil
State/province [30] 0 0
Belo Horizonte
Country [31] 0 0
Brazil
State/province [31] 0 0
Cerqueira Cesar
Country [32] 0 0
Brazil
State/province [32] 0 0
Londrina
Country [33] 0 0
Brazil
State/province [33] 0 0
Santo Andre
Country [34] 0 0
Brazil
State/province [34] 0 0
Sao Paulo
Country [35] 0 0
Canada
State/province [35] 0 0
Alberta
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
Chile
State/province [38] 0 0
Reneca
Country [39] 0 0
Chile
State/province [39] 0 0
Santiago
Country [40] 0 0
China
State/province [40] 0 0
Beijing
Country [41] 0 0
China
State/province [41] 0 0
Guangzhou
Country [42] 0 0
China
State/province [42] 0 0
Hangzhou
Country [43] 0 0
China
State/province [43] 0 0
Jinan
Country [44] 0 0
China
State/province [44] 0 0
Shanghai
Country [45] 0 0
France
State/province [45] 0 0
Chartres
Country [46] 0 0
France
State/province [46] 0 0
Paris
Country [47] 0 0
France
State/province [47] 0 0
Pierre Benite Cedex
Country [48] 0 0
Germany
State/province [48] 0 0
Düsseldorf
Country [49] 0 0
Germany
State/province [49] 0 0
Heidelberg
Country [50] 0 0
Germany
State/province [50] 0 0
Jena
Country [51] 0 0
Germany
State/province [51] 0 0
Karlsruhe
Country [52] 0 0
Germany
State/province [52] 0 0
Mainz
Country [53] 0 0
Germany
State/province [53] 0 0
Villingen-Schwenningen
Country [54] 0 0
Germany
State/province [54] 0 0
Wilhelmshaven
Country [55] 0 0
Hong Kong
State/province [55] 0 0
Chai Wan
Country [56] 0 0
Hong Kong
State/province [56] 0 0
Hong Kong
Country [57] 0 0
Hong Kong
State/province [57] 0 0
Sha Tin
Country [58] 0 0
Korea, Republic of
State/province [58] 0 0
Seoul
Country [59] 0 0
Netherlands
State/province [59] 0 0
Amsterdam
Country [60] 0 0
Netherlands
State/province [60] 0 0
Enschede
Country [61] 0 0
Netherlands
State/province [61] 0 0
Groningen
Country [62] 0 0
Netherlands
State/province [62] 0 0
Maastricht
Country [63] 0 0
Poland
State/province [63] 0 0
Gdansku
Country [64] 0 0
Poland
State/province [64] 0 0
Gliwice
Country [65] 0 0
Poland
State/province [65] 0 0
Krakow
Country [66] 0 0
Poland
State/province [66] 0 0
Olsztyn
Country [67] 0 0
Poland
State/province [67] 0 0
Poznan
Country [68] 0 0
Poland
State/province [68] 0 0
Warszawa Poland
Country [69] 0 0
Poland
State/province [69] 0 0
Wroclaw
Country [70] 0 0
Russian Federation
State/province [70] 0 0
Chelyabinsk
Country [71] 0 0
Russian Federation
State/province [71] 0 0
Moscow N/A
Country [72] 0 0
Russian Federation
State/province [72] 0 0
Moscow
Country [73] 0 0
Russian Federation
State/province [73] 0 0
Obninsk, Kaluga Region
Country [74] 0 0
Russian Federation
State/province [74] 0 0
Orenburg
Country [75] 0 0
Russian Federation
State/province [75] 0 0
Saint Petersburg
Country [76] 0 0
Russian Federation
State/province [76] 0 0
Samara
Country [77] 0 0
Russian Federation
State/province [77] 0 0
St. Petersburg
Country [78] 0 0
Singapore
State/province [78] 0 0
Singapore
Country [79] 0 0
Spain
State/province [79] 0 0
Barcelona
Country [80] 0 0
Spain
State/province [80] 0 0
Girona
Country [81] 0 0
Spain
State/province [81] 0 0
Guadalajara
Country [82] 0 0
Spain
State/province [82] 0 0
L'Hospitalet De Llobregat
Country [83] 0 0
Spain
State/province [83] 0 0
Madrid
Country [84] 0 0
Spain
State/province [84] 0 0
Maranon
Country [85] 0 0
Spain
State/province [85] 0 0
Valencia
Country [86] 0 0
Spain
State/province [86] 0 0
Zaragoza
Country [87] 0 0
Sweden
State/province [87] 0 0
Göteborg
Country [88] 0 0
Sweden
State/province [88] 0 0
Umeå
Country [89] 0 0
Sweden
State/province [89] 0 0
Uppsala
Country [90] 0 0
Taiwan
State/province [90] 0 0
Kaohsiung County
Country [91] 0 0
Taiwan
State/province [91] 0 0
Taipei
Country [92] 0 0
Taiwan
State/province [92] 0 0
Tao-Yuan
Country [93] 0 0
United Kingdom
State/province [93] 0 0
Birmingham
Country [94] 0 0
United Kingdom
State/province [94] 0 0
Edinburgh
Country [95] 0 0
United Kingdom
State/province [95] 0 0
Leicester
Country [96] 0 0
United Kingdom
State/province [96] 0 0
London
Country [97] 0 0
United Kingdom
State/province [97] 0 0
Nottingham
Country [98] 0 0
United Kingdom
State/province [98] 0 0
Poole
Country [99] 0 0
United Kingdom
State/province [99] 0 0
Sheffield

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/industry
Name [1] 0 0
PharmaMar
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial
Address 0 0
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00113607